CY1112412T1 - Διεργασια για την παρασκευη του αλατος ασβεστιου της ροσουβαστατινης - Google Patents

Διεργασια για την παρασκευη του αλατος ασβεστιου της ροσουβαστατινης

Info

Publication number
CY1112412T1
CY1112412T1 CY20111100442T CY111100442T CY1112412T1 CY 1112412 T1 CY1112412 T1 CY 1112412T1 CY 20111100442 T CY20111100442 T CY 20111100442T CY 111100442 T CY111100442 T CY 111100442T CY 1112412 T1 CY1112412 T1 CY 1112412T1
Authority
CY
Cyprus
Prior art keywords
preparation
calcium salt
rosuvastatin calcium
useful
dihydroxyept
Prior art date
Application number
CY20111100442T
Other languages
English (en)
Inventor
John Horbury
Nigel Philip Taylor
Original Assignee
Astrazeneca Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9942204&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1112412(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Uk Limited filed Critical Astrazeneca Uk Limited
Publication of CY1112412T1 publication Critical patent/CY1112412T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Περιγράφεται μία βελτιωμένη διεργασία για την παρασκευή άλατος ασβεστίου (Ε)-7-[4-(4-φθοροφαινυλ)-6-ισοπροπυλ-2-[μεθυλ(μεθυλσουλφονυλ)αμινο]πυριμιδιν-5-υλ](3R,5S)-3,5-διυδροξυεπτ-6-ενοϊκού οξέος, το οποίο είναι χρήσιμο για την παραγωγή ενός φαρμακευτικού προϊόντος χρήσιμου στη θεραπεία, μεταξύ άλλων, της υπερχοληστερολαιμίας, της υπερλιποπρωτεϊναιμίας και της αθηροσκλήρωσης.
CY20111100442T 2002-08-13 2011-05-09 Διεργασια για την παρασκευη του αλατος ασβεστιου της ροσουβαστατινης CY1112412T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0218781.3A GB0218781D0 (en) 2002-08-13 2002-08-13 Chemical process
EP03784274A EP1539711B1 (en) 2002-08-13 2003-08-07 Process for preparing the calcium salt of rosuvastatin

Publications (1)

Publication Number Publication Date
CY1112412T1 true CY1112412T1 (el) 2015-12-09

Family

ID=9942204

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100442T CY1112412T1 (el) 2002-08-13 2011-05-09 Διεργασια για την παρασκευη του αλατος ασβεστιου της ροσουβαστατινης

Country Status (30)

Country Link
US (2) US7511140B2 (el)
EP (1) EP1539711B1 (el)
JP (1) JP4588446B2 (el)
KR (1) KR101325827B1 (el)
CN (1) CN100361979C (el)
AR (1) AR040868A1 (el)
AT (1) ATE501125T1 (el)
AU (1) AU2003251369B2 (el)
BR (1) BR0313394A (el)
CA (1) CA2495296C (el)
CY (1) CY1112412T1 (el)
DE (1) DE60336326D1 (el)
DK (1) DK1539711T3 (el)
ES (1) ES2361009T3 (el)
GB (1) GB0218781D0 (el)
HK (1) HK1082735A1 (el)
IL (1) IL166626A (el)
IS (1) IS7728A (el)
MX (1) MXPA05001582A (el)
MY (1) MY135301A (el)
NO (1) NO329439B1 (el)
NZ (1) NZ538070A (el)
PL (1) PL375296A1 (el)
PT (1) PT1539711E (el)
RU (1) RU2326871C2 (el)
SI (1) SI1539711T1 (el)
TW (1) TWI316058B (el)
UA (1) UA83805C2 (el)
WO (1) WO2004014872A1 (el)
ZA (1) ZA200500745B (el)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
GB0011120D0 (en) * 2000-05-09 2000-06-28 Avecia Ltd Process
NL1015744C2 (nl) 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
ATE349431T1 (de) 2001-07-13 2007-01-15 Astrazeneca Uk Ltd Herstellung von aminopyrimidinverbindungen
EP1323717A1 (en) 2001-12-27 2003-07-02 Dsm N.V. Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
EP1375493A1 (en) 2002-06-17 2004-01-02 Dsm N.V. Process for the preparation of an dioxane acetic acid ester
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
WO2004054986A2 (en) 2002-12-16 2004-07-01 Astrazeneca Uk Limited Process for the preparation of pyrimidine compounds
GB0312896D0 (en) * 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
WO2005023778A2 (en) * 2003-08-28 2005-03-17 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
UY28501A1 (es) * 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0321827D0 (en) * 2003-09-18 2003-10-15 Astrazeneca Uk Ltd Chemical compounds
GB0324791D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
TW200526596A (en) 2003-11-24 2005-08-16 Teva Pharma Crystalline ammonium salts of rosuvastatin
US7244844B2 (en) 2003-12-02 2007-07-17 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
EP1737828A1 (en) * 2004-01-19 2007-01-03 Ranbaxy Laboratories Limited Amorphous magnesium salts of rosuvastatin
US7241800B2 (en) 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
CA2573857A1 (en) 2004-07-13 2006-02-16 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
EP1797046A2 (en) * 2004-09-27 2007-06-20 Ranbaxy Laboratories Limited Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium
US7985418B2 (en) 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
CA2591053C (en) 2004-12-23 2011-03-15 Zhejiang Hisun Pharma. Co., Ltd Pyrimidinone compounds and preparation and use thereof
GB0428328D0 (en) 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
CA2594692A1 (en) * 2005-01-31 2006-08-03 Ciba Specialty Chemicals Holding Inc. Crystalline forms of rosuvastatin calcium salt
KR100945763B1 (ko) 2005-02-22 2010-03-08 테바 파마슈티컬 인더스트리즈 리미티드 로수바스타틴의 제조 방법
JP5416403B2 (ja) 2005-06-24 2014-02-12 レツク・フアーマシユーテイカルズ・デー・デー 純粋な非結晶ロスバスタチンカルシウムの調製方法
CA2612587C (en) * 2005-06-24 2013-02-19 Lek Pharmaceuticals D.D. Process for preparing amorphous rosuvastatin calcium free of impurities
GB0514078D0 (en) * 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
RU2008108078A (ru) * 2005-08-04 2009-09-10 Трансформ Фармасьютикалз, Инк. (Us) Новые препаративные формы, включающие фенофибрат и статин, и соответствующие способы лечения
MX2007004423A (es) 2005-08-16 2007-06-14 Teva Pharma Calcio de rosuvastatina con bajo contenido de sal.
TW200800917A (en) 2005-08-16 2008-01-01 Teva Pharma Crystalline rosuvastatin intermediate
KR101574072B1 (ko) 2005-09-15 2015-12-04 젠자임 코포레이션 아민 중합체에 대한 샤셋 제형
US8455640B2 (en) 2006-05-03 2013-06-04 Msn Laboratories Limited Process for statins and its pharmaceutically acceptable salts thereof
ES2567171T3 (es) 2006-10-09 2016-04-20 Msn Laboratories Private Limited Nuevo procedimiento para la preparación de estatinas y sus sales farmacéuticamente aceptables
US8318933B2 (en) 2006-10-31 2012-11-27 Aurobindo Pharma Ltd Process for preparing rosuvastatin calcium
TW200831469A (en) * 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process
US8212034B2 (en) 2006-12-13 2012-07-03 Aurobindo Pharma Ltd. Process for preparing rosuvastatin calcium
ATE553098T1 (de) 2007-02-08 2012-04-15 Aurobindo Pharma Ltd Verfahren zur herstellung von rosuvastatin- calcium
EP2178846A1 (en) * 2007-07-12 2010-04-28 Teva Pharmaceutical Industries Ltd. Rosuvastatin intermediates and their preparation
HU230981B1 (hu) * 2007-10-12 2019-08-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Eljárás rosuvastatin só előállítására
HU230637B1 (hu) * 2007-10-12 2017-05-29 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Eljárás rosuvastatin intermedierek előállítására
CA2725052C (en) 2008-05-27 2014-09-16 Changzhou Pharmaceutical Factory Co., Ltd. Preparation method of rosuvastatin calcium and its intermediates
WO2010035284A2 (en) * 2008-09-26 2010-04-01 Matrix Laboratories Ltd An improved process for the preparation of rosuvastatin calcium
EP2350025A1 (en) * 2008-09-30 2011-08-03 Aurobindo Pharma Limited An improved process for preparing pyrimidine propenaldehyde
MX2011007478A (es) * 2009-01-15 2011-09-15 Sag Egis Gyogyszergyar Nylvanosan Muekoedoe Reszvenytarsa Proceso para la preparacion de sales de rosuvastatina.
US8487105B2 (en) 2009-01-19 2013-07-16 Msn Laboratories Limited Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof
US8987444B2 (en) 2010-01-18 2015-03-24 Msn Laboratories Private Limited Process for the preparation of amide intermediates and their use thereof
AU2011243948B2 (en) 2010-04-23 2014-07-17 Sun Pharmaceutical Industries Limited Novel intermediates for the preparation of HMG-CoA reductase inhibitors
HU230987B1 (hu) 2010-11-29 2019-08-28 Egis Gyógyszergyár Nyrt. Eljárás nagy tisztaságú gyógyszeripari intermedierek előállítására
CN105377817A (zh) * 2013-03-29 2016-03-02 中化帝斯曼制药有限公司荷兰公司 匹伐他汀和罗素伐他汀的胺盐
TWM477638U (zh) * 2013-12-12 2014-05-01 三緯國際立體列印科技股份有限公司 加熱平台與立體列印裝置
MX2019009213A (es) 2017-01-23 2019-09-27 Dong Wha Pharm Co Ltd Formulación compleja que comprende inhibidor de la hmg-coa reductasa y clopidogrel.
EA202193139A1 (ru) 2019-05-27 2022-03-01 Имматикс Юс, Инк. Вирусные векторы и их применение в адоптивной клеточной терапии
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
WO2022040631A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
SI26268A (sl) 2021-11-18 2023-05-31 Zupet Rok Postopek za pripravo hidratirane oblike perindopril l-arginina

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US663641A (en) * 1900-10-11 1900-12-11 Charles A Ruebekam Burial-casket.
US4645858A (en) 1982-03-22 1987-02-24 G. D. Searle & Co. Pentanedioic acid derivatives
DE3741509A1 (de) 1987-12-08 1989-06-22 Hoechst Ag Verfahren zur herstellung optisch aktiver 3-desmethylmevalonsaeurederivate sowie zwischenprodukte
EP0367895A1 (en) 1988-10-06 1990-05-16 Sandoz Ag Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them
US5026698A (en) 1988-11-02 1991-06-25 Nissan Chemical Industries, Ltd. Thienopyridine type mevalonolactones
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
US5278313A (en) 1992-03-27 1994-01-11 E. R. Squibb & Sons, Inc. Process for the preparation of 1,3-dioxane derivatives useful in the preparation of HMG-COA reductase inhibitors
ATE158579T1 (de) 1992-07-02 1997-10-15 Hoechst Ag Verfahren zur herstellung von (3r,5s)6-hydroxy- 3,5-0-isopropyliden-3,5-dihydroxy-hexansäure- tert.-butylester
SI0848705T1 (en) 1995-07-17 2002-04-30 Warner-Lambert Company Crystalline r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- (phenylamino)carbonyl)-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
US6278001B1 (en) 1995-11-28 2001-08-21 L'oréal Method for preparing (+) compactin and (+) mevinolin analog compounds having a β-hydroxy-δ-lactone grouping
FR2741620B1 (fr) 1995-11-28 1997-12-26 Oreal Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline
US6124340A (en) 1996-06-24 2000-09-26 Astra Aktiebolag Polymorphic compounds
JP4440476B2 (ja) 1998-12-10 2010-03-24 株式会社カネカ シンバスタチンの製造方法
GB9900339D0 (en) * 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
GB9903472D0 (en) * 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
WO2001004100A1 (en) * 1999-07-13 2001-01-18 Lonza Ag Process for preparing 2-amino-4-(4-fluorphenyl)-6-alkylpyrimidine-5-carboxylate
AU7717500A (en) 1999-09-30 2001-04-30 Merck & Co., Inc. Anti-hypercholesterolemic drug combination
ES2349364T3 (es) 1999-11-17 2010-12-30 Teva Pharmaceutical Industries, Ltd. Procedimiento para la preparación de una forma polimórfica de atorvastatina cálcica.
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
AU2000254249A1 (en) 2000-03-28 2001-10-08 Biocon India Limited Synthesis of (r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-
GB0011120D0 (en) * 2000-05-09 2000-06-28 Avecia Ltd Process
GB0011163D0 (en) 2000-05-10 2000-06-28 Astrazeneca Ab Chemical compound
NL1015744C2 (nl) * 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
WO2002030415A1 (en) 2000-10-05 2002-04-18 Biogal Gyogyszergyar Rt Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
US6777552B2 (en) 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
PL362981A1 (en) 2000-11-16 2004-11-02 Teva Pharmaceutical Industries Ltd. Hydrolysis of [r(r*,r*)]-2-(4-fluorophenyl)-beta,delta -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
NL1017548C2 (nl) 2001-03-09 2002-09-10 Synthon Bv Een lactonisatie proces.
IN190564B (el) 2001-04-11 2003-08-09 Cadila Heathcare Ltd
PL367133A1 (en) 2001-06-06 2005-02-21 Bristol-Myers Squibb Company Process for preparing chiral diol sulfones and dihydroxy acid hmg coa reductase inhibitors
ATE349431T1 (de) 2001-07-13 2007-01-15 Astrazeneca Uk Ltd Herstellung von aminopyrimidinverbindungen
NZ529913A (en) 2001-08-16 2005-03-24 Teva Pharma Processes for preparing calcium salt forms of statins
CN1545502A (zh) 2001-08-22 2004-11-10 �������⻯ѧƷ�ع����޹�˾ 吲哚衍生物的制备方法
EP1465667A4 (en) 2001-09-24 2007-06-27 Merck & Co Inc SCREENING AND SELECTION PROCEDURE FOR STATIN COMBINATIONS
EP1323717A1 (en) * 2001-12-27 2003-07-02 Dsm N.V. Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
KR100511533B1 (ko) 2002-04-09 2005-08-31 임광민 키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법
US20050222415A1 (en) 2002-05-21 2005-10-06 Yatendra Kumar Process for the preparation of rosuvastatin
EP1375493A1 (en) * 2002-06-17 2004-01-02 Dsm N.V. Process for the preparation of an dioxane acetic acid ester
GB0218781D0 (en) * 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
SI1578733T1 (sl) 2002-12-10 2011-07-29 Ranbaxy Lab Ltd Postopek za pridobitev rosuvastatina
WO2004054986A2 (en) 2002-12-16 2004-07-01 Astrazeneca Uk Limited Process for the preparation of pyrimidine compounds
EA013500B1 (ru) 2003-04-11 2010-06-30 Лек Фармасьютиклз Д.Д. Способ получения аморфной кальциевой соли аторвастатина
WO2004103977A2 (en) 2003-05-21 2004-12-02 Ciba Specialty Chemicals Holding Inc. Process for the preparation of pyrimidine derivatives
GB0312896D0 (en) * 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
WO2005005384A1 (en) 2003-07-15 2005-01-20 Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S. Process for the preparation of amortphous atorvastatin calcium without interconversion of any crystalline form
WO2005023778A2 (en) 2003-08-28 2005-03-17 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
UY28501A1 (es) * 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0321827D0 (en) * 2003-09-18 2003-10-15 Astrazeneca Uk Ltd Chemical compounds
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
US20070191318A1 (en) 2003-10-22 2007-08-16 Yatendra Kumar Process for the preparation of amorphous rosuvastatin calcium
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
DE10352659B4 (de) 2003-11-11 2007-09-13 Ratiopharm Gmbh Verfahren zur Herstellung von Statinen und Tetrahydropyranonderivate zur Verwendung in dem Verfahren
TW200526596A (en) 2003-11-24 2005-08-16 Teva Pharma Crystalline ammonium salts of rosuvastatin
US7028631B2 (en) * 2003-11-24 2006-04-18 The Boeing Company Gliding submersible transport system
WO2005077916A1 (en) 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Salts of hmg-coa reductase inhibitors and use thereof
US7244844B2 (en) 2003-12-02 2007-07-17 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
WO2005054207A1 (en) 2003-12-04 2005-06-16 Glenmark Pharmaceuticals Limited Process for the preparation of pyrimidine derivatives
EP1697338A2 (en) 2003-12-24 2006-09-06 Teva Pharmaceutical Industries Ltd. Process for preparation of statins with high syn to anti ratio
CZ200486A3 (cs) 2004-01-16 2005-08-17 Zentiva, A.S. Způsob výroby hemivápenaté soli (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-6-heptenové kyseliny
EP1737828A1 (en) 2004-01-19 2007-01-03 Ranbaxy Laboratories Limited Amorphous magnesium salts of rosuvastatin
US7241800B2 (en) 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
GB0406757D0 (en) 2004-03-26 2004-04-28 Avecia Ltd Process and compounds
US7161004B2 (en) 2004-06-21 2007-01-09 Dr. Reddy's Laboratories Limited Processes to produce intermediates for rosuvastatin
CA2573857A1 (en) 2004-07-13 2006-02-16 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
EP1797046A2 (en) 2004-09-27 2007-06-20 Ranbaxy Laboratories Limited Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium
GB0428328D0 (en) 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
CA2594692A1 (en) 2005-01-31 2006-08-03 Ciba Specialty Chemicals Holding Inc. Crystalline forms of rosuvastatin calcium salt
CA2498978A1 (en) 2005-02-28 2006-08-28 Apotex Pharmachem Inc. An improved process for the preparation of atorvastatin and intermediates
GB0514078D0 (en) * 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
TW200831469A (en) * 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process

Also Published As

Publication number Publication date
ATE501125T1 (de) 2011-03-15
US20060116391A1 (en) 2006-06-01
US7842807B2 (en) 2010-11-30
SI1539711T1 (sl) 2011-06-30
RU2326871C2 (ru) 2008-06-20
RU2005102391A (ru) 2005-10-10
KR101325827B1 (ko) 2013-11-05
WO2004014872A1 (en) 2004-02-19
ZA200500745B (en) 2006-03-29
TW200404786A (en) 2004-04-01
BR0313394A (pt) 2005-06-21
JP4588446B2 (ja) 2010-12-01
CA2495296A1 (en) 2004-02-19
IL166626A0 (en) 2006-01-15
AU2003251369A1 (en) 2004-02-25
NO329439B1 (no) 2010-10-18
AR040868A1 (es) 2005-04-20
EP1539711B1 (en) 2011-03-09
CA2495296C (en) 2011-05-03
PL375296A1 (en) 2005-11-28
DK1539711T3 (da) 2011-05-30
EP1539711A1 (en) 2005-06-15
CN100361979C (zh) 2008-01-16
KR20050036968A (ko) 2005-04-20
NZ538070A (en) 2006-08-31
IL166626A (en) 2011-09-27
IS7728A (is) 2005-03-08
US7511140B2 (en) 2009-03-31
JP2006500347A (ja) 2006-01-05
NO20050542L (no) 2005-02-28
TWI316058B (en) 2009-10-21
HK1082735A1 (en) 2006-06-16
UA83805C2 (uk) 2008-08-26
MXPA05001582A (es) 2005-04-25
CN1688551A (zh) 2005-10-26
AU2003251369B2 (en) 2007-02-01
GB0218781D0 (en) 2002-09-18
ES2361009T3 (es) 2011-06-13
MY135301A (en) 2008-03-31
PT1539711E (pt) 2011-05-03
DE60336326D1 (de) 2011-04-21
US20090286819A1 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
CY1112412T1 (el) Διεργασια για την παρασκευη του αλατος ασβεστιου της ροσουβαστατινης
MXPA05013128A (es) Produccion mejorada de sal calcica de rosuvastatina.
IL175086A0 (en) Process for the manufacture of the calcium salt of rosuvastatin (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl (methylsulfonyl) amino]pyrimidin-5-yl] 3r,5s)- 3,5-dihydroxyhept-6-enoic acid and crystalline intermediates thereof
DK1144389T3 (da) Krystallinsk bis(E)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-ensyre]calciumsalt
DE60140581D1 (de) Pharmazeutische Zusammensetzungen beinhaltend Kristallsalze von 7-Ä4-(4-Fluorophenyl)-6-isopropyl-2-Ämethyl(methylsulfonyl)aminoÜpyrimidin-5-ylÜ-(3R,5S)-3,5-dihydroxyhept-6-ensäure
CY1108733T1 (el) Διαδικασια για την παραγωγη τριτο-βουτυλ (ε)-(6-[2-[4-(4-φθοροφαινυλ)-6-ισοπροπυλ-2-[μεθυλ (μεθυλσουλφονυλ) αμινο] πυριμιδιν-5-υλ] βινυλ](4r, 6s)-2,2-διμεθυλ [1,3]διοξαν-4-υλ) οξικου αλατος
IS2689B (is) Kristallað form bis [(E)-7-[4-(4-flúorfenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl) amínó]pýrimídin-5-ýl](3R, 5S)-3,5-díhýdroxýhept-6-ensýru] kalsíumsalts
MY134902A (en) Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia
CY1110992T1 (el) ΣΥΝΔΥΑΣΜΕΝΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΠΕΡΙΕΧΟΥΝ (Ε)-7-[4-(4-ΦΘΟΡΟΦΑΙΝΥΛ)-6-ΙΣΟΠΡΟΠΥΛ-2-[ΜΕΘΥΛ(ΜΕΘΥΛΣΟΥΛΦΟΝΥΛ)ΑΜΙΝΟ]ΠΥΡΙΜΙΔΙΝ-5-ΥΛ](3r,5s)-3,5-ΔΙΥΔΡΟΞΥΕΠΤ-6-ΕΝΟΪΚΟ ΟΞΥ
AP1879A (en) Pharmaceutical compositions comprising a HMG CoA reductase inhibitor.
NO20061324L (no) Polymorfe former av en kjent antihyperlinemisk forbindelse
UA89614C2 (ru) Способ получения кальциевой соли розовастатина
TH67416A (th) กรรมวิธีสำหรับการเตรียมเกลือแคลเซียมของโรซูวาสเตติน